Novacap, a global player in the pharmaceutical synthesis and specialty ingredients, with a portfolio of products and services and a range of technologies, will combine its Contract Development and Manufacturing Organization (CDMO) subsidiaries—PCI Synthesis, PCAS, Uetikon, and Proteus—into a new entity to be known as SEQENS.
The name change is effective December 19, 2018 but will be rolled out during Q1 2019 at each of SEQENS’ 24 manufacturing plants and three R&D centers in Europe, North America, and Asia. At that time, signage and websites will be updated to reflect the new corporate entity.
The move positions SEQENS as an integrated global company in pharmaceutical synthesis and specialty ingredients, delivering performance, market responsiveness, and solutions. By consolidating its offerings, the company announced it can better serve its customers with global access to its 3,200 employees, including more than 300 scientists, engineer, and experts, and ensure that products are successfully transferred into production.
The SEQENS name was selected to better reflect the company’s core synthesis activities, combined with the sequencing of molecules, competencies, and technologies.
In the pharmaceutical industry, SEQENS supports its customers for the development, scale-up, and manufacturing of drug substances from preclinical through to the commercial phase and offers a significant portfolio of APIs and proprietary products.
The management teams of PCI Synthesis, PCAS, Uetikon and Proteus will remain in place, and continue to report to SEQENS CEO Pierre Luzeau, who previously served as CEO of Novacap.